Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label pazopanib monotherapy in unresectable or metastatic solitary fibrous tumor and extraskeletal myxoid chondrosarcoma
2013-005456-15Phase 2Active
- Sponsor
- Spanish Group for Research on Sarcoma
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in hemangiopericytoma (HPC) and extraskeletal myxoid chondrosarcoma (EMC), sponsored by Spanish Group for Research on Sarcoma. Primary endpoint: Objective response rate. Started Feb 2014; status: active.
02
Drugs
pazopanib
03
Conditions
hemangiopericytoma (HPC)extraskeletal myxoid chondrosarcoma (EMC)
Beyond the preview
Go deeper on 2013-005456-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005456-15.